Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).

Hiroshi MatsuokaTakeshi YamadaRyo OhtaYoichiro YoshidaTatsuyuki WatanabeMakoto TakahashiChihiro KosugiAtsuko FukazawaHidekazu KuramochiAkihisa MatsudaHiromichi SonodaHiroshi YoshidaSuguru HasegawaKazuhiro SakamotoToshiaki OtsukaKeiji HirataKeiji Kodanull null

Published in: International journal of clinical oncology (2022)

Biweekly TAS-102 and bevacizumab therapy as third-line chemotherapy appears as effective as conventional TAS-102 and bevacizumab therapy, and this approach reduces adverse hematological effects.

Keyphrases

phase ii
clinical trial
metastatic colorectal cancer
open label
double blind
locally advanced
phase iii
randomized controlled trial
placebo controlled
stem cells
emergency department
study protocol
squamous cell carcinoma
cell therapy
mesenchymal stem cells
bone marrow
replacement therapy